Connect Biopharma vs Traws Pharma
CNTB and TRAW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNTB and TRAW compare
Connect Biopharma scores higher on the StockData Score (6 against 5 for Traws Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNTB | TRAW |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.9M |
| Share price | $0.677 | $0.251 |
| Change, 1 year | −57.9% | −88.3% |
| Change, 5 years | −86.8% | −99.7% |
| Beta (5Y) | 0.53 | 1.19 |
| Employees | – | 7 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 50.3% | – |
| Revenue growth, 5Y average | – | 64.6% |
| Profitability | ||
| Operating margin | −2384% | – |
| Net margin | −2336% | – |
| FCF margin | −2053% | – |
| Return on equity | −141% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 2.37 (better) | 0.93 |
| Altman Z-score | – | −85.39 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −109% |
| Shareholder yield | – | −109% |
| Ownership | ||
| Held by institutions | 22.1% | 40.1% |
| Held by insiders | 31.6% | 35.7% |
| Insider net buying, 12 months | $4.4M (better) | $998K |
| Short interest, % of float | – | 6.9% |
Go deeper
- CNTB stock overview
- CNTB income statement
- CNTB valuation and score
- TRAW stock overview
- TRAW income statement
- TRAW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.